Plain-English translation of NCT06252649 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether —a new pill that targets a specific genetic mutation in cancer cells—works better when combined with standard chemotherapy and another medication, compared to chemotherapy alone. The study focuses on people with advanced colorectal cancer that has spread to other parts of the body and carries a particular KRAS genetic change. If this treatment works as hoped, it could help people with this type of cancer live longer without their disease worsening.
Currently, people with this specific type of advanced colorectal cancer don't have many treatment options tailored to their genetic mutation. This medication is designed to directly target the faulty gene that drives the cancer, and researchers want to see if adding it to standard chemotherapy can help patients better than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll be randomly assigned to one of two treatment groups. One group takes a daily oral pill along with intravenous chemotherapy infusions every two weeks; the other receives standard chemotherapy alone or with an additional medication. You'll have regular clinic visits for treatment, blood tests, and imaging scans to monitor how well the treatment is working. The study will track how long your cancer stays under control and how you tolerate the medications.
AI-generated summary from trial data · Oct 3, 2026 · Not medical advice
United States